Skip to main content

Table 1 Demographic and clinical data of GIST patients of sub-cohort I (<50 years, “young” ) and sub-cohort II (≥50 years, “old” )

From: Impact of age and gender on tumor related prognosis in gastrointestinal stromal tumors (GIST)

  Parameter Sub-cohort I (n = 87) Sub-cohort II (n = 125)
   <50 yr(“young”) ≥50 yr(“old”)
Age      
  median (range, yr) 41.7 (14.9;49.9) 68.2 (50.9; 94.1)
Sex n % n %
  female 48 55.2 68 54.4
  male 39 44.8 57 45.6
Localization      
  stomach 43 50.6 79 64.2
  small intestine 29 34.1 35 28.5
  colorectum 5 5.9 2 1.6
  esophagus 1 1.2 1 0.8
  EGIST 3 3.5 3 2.4
  n.d. 4 4.7 3 2.4
Tumor size     
  median (range, cm) 5.5 (1.2; 27.0) 4.5 (0.4;40.0)
Risk according to Fletcher et al. [23] n % n %
  high 29 41.4 35 31.8
  intermediate 15 21.4 25 22.7
  low 17 24.3 31 28.2
  very Low 9 12.9 19 17.3
Risk according to Miettinen et al. [11]     
  high 22 33.3 30 29.7
  intermediate 10 15.2 7 6.9
  low 25 37.9 43 42.6
  very Low 9 13.6 21 20.8
Histological subtype     
  spindle cell 63 85.1 98 89.1
  Epithelioid/mixed 11 14.9 12 10.9
Immunohistochemistry     
  KIT pos 74 94.9 115 98.3
  KIT neg 4 5.1 2 1.7
  CD34 pos 48 82.8 84 84.0
  CD34 neg 10 17.2 16 16.0
  S100 pos 11 25.6 1 1.4
  S100 neg 32 74.4 68 98.6
Clinical data     
  Metastasis atdiagnosis 9 10.3 16 12.8
  Secondneoplasia 11 15.5 45 38.8
  R0resection 81 93.1 112 89.6
  Tumor debulking 4 4.6 7 7.2
  Imatinib use 24 27.6 27 21.6
Recurrenceof disease and/ormetastasis     
  yes 21 25.9 32 29.6
Follow up time     
  mean (yr, ±SD) 4.90 (3.39) 5.65 (4.55)
  median (range, yr) 4.28 (0.59;16.31) 4.57 (0.56;21.33)
  deceased 9 10.3 40 32.0
  alive 78 89.7 85 68.0
  tumor-relateddeath 5 5.7 20 16.0
Survival rate % (n) % (n)
DSS (yr1/yr3/yr5) 98.5 (64)/96.6 (49)/96.6 (34) 96.2 (93)/87.0 (67)/81.2 (44)
DFS (yr1/yr3/yr5) 88.4 (57)/81.2 (41)/78.8 (29) 79.0 (74)/74.2 (55)/69.9 (36)
OS (yr1/yr3/yr5) 98.5 (64)/93.2 (49)/91.2 (34) 90.8 (93)/77.4 (67)/67.0 (44)
Syndromal disease 3xNF1 3.4% 3x NF1 2.4%
     1x Carney 1%
  1. yr, year; n.d., not defined; SD, standard deviation; DSS, disease specific survival; DSF, disease free survival; OS, overall survival; NF1, neurofibromatosis type 1; Carney, Carney triad (coexistence of GIST, paraganglioma and pulmonal chondroma).